DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

NCT04258371 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Risk Factor

Interventions

DRUG: Dapagliflozin 10 MG
DRUG: Placebo oral tablet

Sponsor

University Health Network, Toronto

Collaborators

[object Object]
[object Object]